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Background
Chronic volume overload caused by insufficient cardiac
valves is a well known pathomechanism to the develop-
ment and progress of cardiac dilation. Recent studies sug-
gest that PDE-5-inhibitors may have positive inotrope and
cardioprotective effects. Nevertheless the long-term out-
come of PDE-5 treatment in heart failure remains
unknown. In this study we investigated the effects of
chronic vardenafil treatment on myocardial dysfunction
in rats developing heart failure on account of a surgically
induced AV-shunt.
Materials and methods
In young male Sprague-Dawley rats heart failure was
developed during a 3 months period after surgically
inducing an AV-shunt between the inferior caval vein and
abdominal aorta. In the treatment group vardenafil (10
mg/kg/d) was applied orally for 3 months. Control ani-
mals received vehicle instead. After the treatment left ven-
tricular pressure-volume relations were measured using a
microtip Millar conductance catheter. Baseline hemody-
namic parameters and indexes of contractility were calcu-
lated.
Results
Treatment with vardenafil resulted in a significant
increase in load independent indexes of contractility and
efficiency (ESPVR: 1.07 ± 0.14 vs. 1.67 ± 0.12 mmHg/μl*;
efficiency: 45.0 ± 6.0 vs. 65.0 ± 5.0%*; PRSW: 65.40 ±
15.58 vs. 81.07 ± 13.72 mmHg, dPdt/EDV: 45.11 ± 9.57
vs. 48.74 ± 14.51 mmHg; control vs. treatment; *p <
0.05). Furthermore a reduced left ventricular dilatation
and increased ejection fraction has been proven (EDV:
295.89 ± 53.55 vs. 257.91 ± 45.77 μl; EF: 50.99 ± 3.54 vs.
56.45 ± 4.00%; control vs. treatment).
Conclusion
Our current result further support the concept that
chronic downregulation of intracellular cGMP signalling
may play an important role in the development of ven-
tricular dilation and myocardial dysfunction induced by
chronical volume overload. Therefore PDE-5-inhibition
could represent a novel therapeutic approach in the treat-
ment of heart failure.
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